Elite Pharmaceuticals, Inc. (ELTP)

Elite Pharmaceuticals, Inc. (ELTP) Healthcare & Pipeline Overview

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and manufacturing oral, controlled-release, and generic products. It operates across ANDA and NDA segments, offering a diverse portfolio for pain, bariatrics, cardiovascular, and CNS conditions, alongside contract manufacturing and abuse-deterrent opioid development.

What Is the Investment Thesis for ELTP?

Elite Pharmaceuticals, Inc. operates within the dynamic specialty and generic pharmaceutical sector, leveraging its expertise in oral, controlled-release formulations and a diverse product portfolio. The company's financial profile, characterized by a market capitalization of $393.14M, a P/E ratio of 8.8, a profit margin of 31.0%, and a gross margin of 51.1%, reflects its operational efficiency and market valuation. Key value drivers include its established generic product lines for bariatrics, pain, and cardiovascular conditions, which provide consistent revenue streams. Significant growth catalysts are anticipated from the advancement and potential commercialization of its abuse-deterrent opioid pipeline, addressing a critical market need and offering premium pricing opportunities. Further growth is expected from expanding its contract manufacturing services, utilizing its specialized facilities to serve more third-party clients. However, investors may want to evaluate risks such as intense competition in the generic market, potential regulatory hurdles for pipeline products, and the inherent challenges associated with its OTC market listing, including liquidity and disclosure limitations.

Based on FMP financials and quantitative analysis

ELTP Key Highlights

• Market capitalization of $393.14M, reflecting its position as a smaller-cap specialty pharmaceutical company.
• A P/E ratio of 8.8, indicating its earnings valuation relative to its share price.
• Profit margin of 31.0%, demonstrating profitability from its operations.
• Gross margin of 51.1%, highlighting the efficiency of its production and sales processes.
• A Beta of 0.38, suggesting lower volatility compared to the broader market.

Who Are ELTP's Competitors?

ELTP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ELTP's Key Strengths?

• Specialized expertise in oral, controlled-release drug development and manufacturing.
• Diverse portfolio of generic pharmaceuticals addressing multiple therapeutic areas.
• Contract manufacturing services provide a stable, diversified revenue stream.
• Development pipeline focused on abuse-deterrent opioid products, addressing a high-demand area.

What Are ELTP's Weaknesses?

• Relatively small company size (64 employees) compared to larger pharmaceutical competitors.
• Reliance on the highly competitive generic drug market, which can face pricing pressures.
• OTC market listing may impact liquidity, investor perception, and access to capital.
• Unknown disclosure status for OTC market, potentially limiting investor information.

What Could Drive ELTP Stock Higher?

• Regulatory milestones or approvals for pipeline products, particularly the abuse-deterrent opioid formulations.
• Launch of new generic products following successful Abbreviated New Drug Application (ANDA) approvals.
• Securing new contract manufacturing agreements with third-party pharmaceutical companies, expanding service revenue.
• Expansion of market penetration and sales for the existing generic product portfolio through enhanced distribution.

What Are the Key Risks for ELTP?

• Failure to obtain regulatory approval for pipeline products, especially the abuse-deterrent opioid candidates, impacting future revenue streams.
• Intense competition and persistent pricing pressure within the highly competitive generic pharmaceutical market.
• Risks associated with operating on the OTC market, including limited liquidity, potential for wider bid-ask spreads, and reduced investor confidence.
• Adverse changes in healthcare regulations, drug pricing policies, or opioid prescribing guidelines by regulatory bodies.
• Dependence on a limited number of key products or contract manufacturing clients, leading to revenue concentration risk.

What Are the Growth Opportunities for ELTP?

• Development of Abuse-Deterrent Opioids: The company is actively developing abuse-deterrent opioid products, a segment driven by public health concerns and regulatory initiatives to combat opioid misuse. This market is poised for growth as healthcare providers and regulators seek safer pain management solutions. Successful development and commercialization of these products could allow Elite to capture a significant share of a premium market, potentially within a 3-5 year timeline for regulatory approval and market entry, providing a substantial new revenue stream and enhancing its market position in pain management.
• Expansion of Contract Manufacturing Services: Elite Pharmaceuticals, Inc. currently manufactures controlled-release products on a contract basis for third parties across various therapeutic areas, including pain, allergy, bariatric, and infection. Expanding this segment represents a robust growth opportunity by leveraging the company's specialized manufacturing capabilities and expertise in complex oral dose formulations. As pharmaceutical companies increasingly outsource specialized production, Elite can capitalize on this trend to secure more contracts, diversify its revenue base, and optimize capacity utilization. This ongoing growth avenue could see new partnerships and increased production volumes over the next 1-3 years.
• Diversification and Launch of New Generic Products: The company's Abbreviated New Drug Applications (ANDA) segment enables it to develop and commercialize generic versions of existing branded drugs. With an established portfolio of generics for bariatrics, pain, and cardiovascular conditions, identifying and pursuing new generic drug opportunities is a consistent growth driver. The generic drug market continues to expand due to patent expirations and global healthcare cost-containment efforts. Successfully launching new generic products, especially those with complex formulations or limited competition, can provide a steady and predictable revenue stream, typically within a 1-2 year timeframe post-approval.
• Leveraging Existing Product Portfolio in Niche Markets: Elite Pharmaceuticals holds, licenses, and contract manufactures several generic and oral dose pharmaceutical products, such as Phentermine HCl for bariatrics and Naltrexone HCl for pain. Optimizing market penetration and sales for these established products within their respective niche markets can yield incremental growth. This involves strategic marketing, enhancing distribution channel effectiveness, and potentially exploring new indications or improved formulations where scientifically and commercially viable. The bariatric and pain management markets, while competitive, offer consistent demand for proven and effective generic treatments, providing an ongoing avenue for revenue stability and growth.
• Strategic Partnerships and Licensing Agreements: Elite Pharmaceuticals could pursue strategic partnerships or in-licensing opportunities to broaden its product pipeline or extend its market reach. Collaborating with other pharmaceutical companies for co-development, co-promotion, or licensing new drug candidates can accelerate growth without solely relying on internal research and development. Such alliances can provide access to novel technologies, expand into new therapeutic areas, or facilitate entry into new geographic markets. Given the capital-intensive nature of drug development, strategic collaborations offer a capital-efficient method to expand operations, with potential impacts on revenue and market share over a 2-4 year horizon depending on the nature of the partnership.

What Opportunities Does ELTP Have?

• Increasing demand for abuse-deterrent opioid formulations due to public health initiatives and regulatory support.
• Expansion of contract manufacturing services to new clients or product types, leveraging existing capabilities.
• Introduction of new generic products as patents expire for branded drugs, expanding market share.
• Potential for strategic partnerships or licensing deals to expand pipeline and market reach more efficiently.

What Threats Does ELTP Face?

• Intense competition from larger generic and specialty pharmaceutical companies.
• Regulatory changes impacting drug approvals, pricing, or opioid prescribing policies.
• Failure of R&D pipeline products (e.g., abuse-deterrent opioids) to achieve regulatory approval or market acceptance.
• Ongoing pricing pressures and market erosion in the generic drug sector.

What Are ELTP's Competitive Advantages?

• Specialized expertise in developing and manufacturing complex oral, controlled-release formulations.
• Existing portfolio of approved generic drugs with an established market presence in specific therapeutic areas.
• Ongoing development of abuse-deterrent opioid technologies, addressing a critical and evolving market need.
• Contract manufacturing capabilities provide a diversified revenue stream and leverage specialized facilities and regulatory knowledge.

What Does ELTP Do?

Elite Pharmaceuticals, Inc., incorporated in 1997 and headquartered in Northvale, New Jersey, is a specialty pharmaceutical company dedicated to the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company strategically operates in two distinct segments: Abbreviated New Drug Applications (ANDA) for generic products and New Drug Applications (NDA) for branded products, allowing it to address both cost-effective generic markets and innovative branded solutions. Elite's comprehensive product portfolio includes a range of owned, licensed, and contract-manufactured generic and oral dose pharmaceuticals. Key offerings include Phentermine HCl 37.5mg tablets, marketed under the Adipex-P brand for bariatrics, and Phendimetrazine Tartrate 35mg tablets, under the Bontril brand, also for bariatric treatment. For pain management, the company provides Naltrexone HCl 50mg tablets (Revia brand) and various strengths of Oxycodone HCl immediate release tablets (5mg, 10mg, 15mg, 20mg, and 30mg) under the Roxycodone brand. Its cardiovascular portfolio includes Isradipine 2.5mg and 5mg capsules. Elite also addresses central nervous system diseases with products like Trimipramine Maleate Immediate Release antidepressant capsules (Surmontil brand) and Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets (Adderall brand). Other specialized products include Dantrolene Sodium capsules (Dantrium brand) for muscle relaxation, SequestOX (an immediate release Oxycodone with Naltrexone), Loxapine Succinate capsules for antipsychotic treatment (Loxapine brand), Acetaminophen and Codeine Phosphate for mild to moderate pain, and a range of antibiotic products. Beyond its own product lines, Elite Pharmaceuticals serves as a contract manufacturer for third parties, producing controlled-release products in therapeutic areas such as pain, allergy, bariatric, and infection. A significant strategic focus for the company is the ongoing development of a range of abuse-deterrent opioid products, aiming to address critical public health concerns related to opioid misuse.

What Products and Services Does ELTP Offer?

• Develop and manufacture oral, controlled-release pharmaceutical products.
• Produce generic pharmaceuticals under Abbreviated New Drug Applications (ANDA).
• Develop branded pharmaceutical products under New Drug Applications (NDA).
• Own and license a portfolio of generic drugs for bariatrics, pain, and cardiovascular diseases.
• Contract manufacture controlled-release products for other pharmaceutical companies.
• Actively developing a range of abuse-deterrent opioid products.
• Offer products like Phentermine HCl, Naltrexone HCl, and various opioid formulations.

How Does ELTP Make Money?

• Generate revenue from the direct sale of proprietary generic pharmaceutical products.
• Earn income through contract manufacturing services for third-party controlled-release products.
• Monetize licensed pharmaceutical products through sales and distribution agreements.
• Aim to derive future revenue from the successful development and commercialization of new branded and abuse-deterrent products.

What Industry Does ELTP Operate In?

Elite Pharmaceuticals, Inc. operates within the highly competitive and regulated Drug Manufacturers - Specialty & Generic industry. The broader healthcare sector is experiencing trends such as increasing demand for cost-effective generic alternatives due to healthcare cost containment pressures, a growing focus on advanced drug delivery systems like controlled-release formulations for improved patient compliance, and a critical need for abuse-deterrent formulations, particularly for opioid products. Elite positions itself as a niche player, specializing in complex oral dose and controlled-release technologies, which differentiates it from broader generic manufacturers. The competitive landscape includes large generic pharmaceutical companies and other specialty pharma firms. Elite's strategic focus on developing abuse-deterrent opioids aligns with a significant market trend and regulatory push, potentially allowing it to capture a specialized segment within the pain management market.

Who Are ELTP's Key Customers?

• Wholesale pharmaceutical distributors.
• Retail pharmacies and hospital systems.
• Other pharmaceutical companies requiring contract manufacturing services.
• Patients, indirectly, through prescriptions for their generic and branded products.

How Elite Pharmaceuticals, Inc. Is Valued

Elite Pharmaceuticals, Inc. carries a market capitalization of $393.14M, placing it in the small-cap category. Relative to its peer group, ELTP's quantitative score of 53/100 is below the peer average of 66/100.

Company Profile

Elite Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Northvale, US. The company is led by CEO Nasrat Hakim. ELTP has traded publicly since 2000.

ROE 0%Key Financial Metrics

Return on equity for Elite Pharmaceuticals, Inc. stands at 0.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. ELTP trades at a trailing price-to-earnings ratio of 8.76, below the Healthcare sector average of ~23x. A current ratio of 6.45 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 10.9%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 6/9Financial Health

Elite Pharmaceuticals, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 6.34 places it in the safe zone, indicating low near-term bankruptcy risk.

BalancedInsider Activity

Over the past six months, Elite Pharmaceuticals, Inc. insiders filed 2 SEC Form 4 transactions — 1 sales and 1 purchases. Buying and selling roughly offset over the period, so insider signaling is neutral.

ELTP Financials

ELTP Latest News

ELTP Analyst Consensus

ELTP MoonshotScore

Elite Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources